Identify the exact product
Ask for the cell type, donor source, processing method, dose, route of administration and manufacturing centre. “Stem cells” alone is not an adequate description.
Stem Cell & Regenerative Medicine · Turkey
Evidence before treatment.
Stem cell is not one medicine or one procedure. We help patients inspect the cell source, intended use, evidence, authorisation and treating centre before considering travel.
Start here
A condition appearing on this page does not mean stem cell treatment is proven, approved or suitable.
Some cell therapies have established roles for specific blood and immune disorders. Many regenerative applications promoted for neurological, pulmonary, orthopaedic, reproductive, ophthalmic or cosmetic conditions remain experimental, condition-specific or unsupported. Eligibility can only follow review by an appropriately authorised clinical team.
Verify authorisation
Confirm the hospital, human-application centre and tissue/cell facility are licensed for the proposed activity, and whether the use is standard care, a treatment trial or clinical research.
Inspect the evidence
Look for condition-specific human evidence, recognised endpoints, published adverse events and independent oversight. Testimonials cannot establish safety or effectiveness.
Indications patients ask about
Six clinical pathways for evidence and eligibility review.
These groups reflect enquiries that regenerative-medicine centres may receive. They are not a list of treatments Aestheticsbridge guarantees or recommends.
Vascular, wound and tissue repair
Specialist evidence review required- Peripheral arterial disease, including Buerger disease
- Chronic critical limb ischaemia and foot ulcers
- Diabetic foot wounds
- Soft-tissue wounds and surgical-wound repair
- Burns, traumatic wounds and scar repair
- Selected reconstructive applications, including breast reconstruction
Orthopaedic and musculoskeletal questions
Many uses remain investigational- Cartilage degeneration
- Tendon injury
- Muscle injury and selected myopathies
- Duchenne muscular dystrophy (DMD)
- Limb-girdle muscular dystrophy (LGMD)
- Miyoshi myopathy
Neurological and developmental conditions
Clinical-trial or specialist pathway only- Spinal cord injury
- Cerebral palsy
- Traumatic brain injury
- Hypoxic-ischaemic encephalopathy
- Spinocerebellar and Friedreich ataxia
- Multiple sclerosis, stroke, autoimmune encephalitis and SSPE
- Autism spectrum disorder
Pulmonary and cardiovascular conditions
Evidence and authorisation must be verified- Chronic obstructive pulmonary disease (COPD)
- Idiopathic pulmonary fibrosis (IPF)
- Cystic fibrosis
- Ischaemic cardiac disease
- Peripheral arterial disease
Ophthalmic, reproductive and systemic conditions
Not routine stem-cell treatment- Optic atrophy and retinitis pigmentosa
- Ovarian insufficiency
- Erectile dysfunction
- Systemic sclerosis / scleroderma
- Crohn's disease
- Short bowel syndrome
- Selected immune-support questions such as graft-versus-host disease
Reconstructive and cosmetic enquiries
Product and claim verification required- Skin rejuvenation and tightening
- Hand rejuvenation
- Facial bone and soft-tissue trauma
- Maxillofacial reconstruction
- Hair restoration
- Plastic-surgery wound support
How we classify an enquiry
Three statuses. No blurred language.
A recognised indication with an authorised product or transplantation pathway and accepted clinical governance.
A proposed application studied through a properly registered, ethics-approved protocol with transparent eligibility and monitoring.
Evidence, product identity, authorisation or oversight cannot be verified. We do not present this as a treatment option.
Before specialist review
What records may be needed
- Confirmed diagnosis, specialist letters and previous treatment history
- Relevant MRI, CT, pathology, pulmonary, cardiac, vascular or ophthalmic testing
- Current medicines, allergies, infections and immune status
- Functional assessments and recent laboratory results
- The exact proposed product or protocol, if another provider has already made an offer
Patient-safety sources
Inspect the regulatory context.
ISSCR — Stem Cell Resources for Patients FDA — Consumer Alert on Regenerative Medicine Products Republic of Türkiye Ministry of Health — Human Tissue and Cell RegulationThis educational platform does not diagnose, recommend or sell an unapproved cell product. A licensed specialist and authorised centre must determine whether any regulated pathway exists for an individual patient.
Ask for an evidence and eligibility review
Share the diagnosis and existing medical records. We will first clarify what type of specialist, authorisation and evidence should be checked—before discussing travel.